Objective： To observe the clinical effect of Yaobitong capsules combined with meloxicam for ankylosing spondylitis(AS)characterized by inflammatory back pain.Methods：A total of 38 cases of AS patients characterized by inflammatory back pain were selected and randomly divided into the control group and the observation group，19 cases in each group.The control group was simply treated with meloxicam，and the observation group was additionally treated with Yaobitong capsules based on the treatment of the control group.Both groups were treated for four weeks.The clinical effect in the two groups was compared.The improvement of the Bath Ankylosing Spondylitis Disease Activity Index(BASDAI)，the Bath Ankylosing Spondylitis Functional Index(BASFI)，the duration of morning stiffness and laboratory indexes was observed.The incidence of adverse reactions was recorded.Results：The effective rate was 84.21% in the observation group，higher than that of 52.63% in the control group(P＜ 0.05).After treatment，the BASDAI and BASFI in the two groups were decreased when compared with those before treatment(P＜0.05，P＜0.01)，and the duration of morning stiffness was shortened when compared with that before treatment(P ＜ 0.01)；the BASDAI and BASFI in the observation group were lower than those in the control group(P＜0.01)，and the duration of morning stiffness was shorter than that in the control group(P＜0.01).After treatment，the levels of erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)in the two groups were decreased when compared with those before treatment(P＜ 0.01)；the above two levels in the observation group were lower than those in the control group(P＜0.05).There was no severe adverse reaction during the treatment in the two groups.Conclusion：The therapy of Yaobitong capsules combined with meloxicam has better curative effect in treating AS characterized by inflammatory back pain.